Watchdog told Medicare and Medicaid EpiPen was improperly classified in 2009: 4 things to know

Written by Eric Oliver | November 09, 2016 | Print  |

The internal watchdog at HHS allegedly told CMS that Canonsburg, Pa.-based Mylan Pharmaceuticals had been improperly classifying its EpiPen since 2009, Reuters reports.

Here's what you need to know.

1. HHS Inspector General Daniel R. Levinson told Senator Charles Grassley (R-Iowa) of the findings Oct. 8, 2016. Mylan agreed to a $465 million settlement with CMS last month.

2. The disclosure from HHR raise questions on why Mylan took so long to correct the error, what steps CMS took to inform Mylan of the error and why Mylan didn't disclose the information with its investors.

3. U.S. Securities regulators issued a subpoena for Mylan's communications with CMS.

4. CMS told Reuters it had told Mylan several times of the misclassification.

More articles on practice management:
Drs. Sonia Szlyk, Ryan Nunley to present on regional anesthesia in orthopedic care: 4 notes
8 states with premium hikes exceeding 30%
How Dr. Louis Levitt leads a large orthopedic practice — The Center for Advanced Orthopaedics: 5 key notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers